Q1 2024 Holdings
Filed 2024-05-15 | 38 holdings | $622.0M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Cullinan Oncology, Inc.(CGEM) | Common | 230031106 | $130.3M | 7,648,268 | 21.0% |
| Geron Corporation(GERN) | Common | 374163103 | $34.6M | 10,475,675 | 5.6% |
| Iovance Biotherapeutics Inc(IOVA) | Common | 462260100 | $32.6M | 2,200,000 | 5.2% |
| Zentalis Pharmaceuticals, Inc.(ZNTL) | Common | 98943L107 | $23.9M | 1,516,183 | 3.8% |
| iTeos Therapeutics, Inc.(5E7) | Common | 46565G104 | $23.8M | 1,745,943 | 3.8% |
| Sutro Biopharma, Inc. | Common | 869367102 | $23.1M | 4,096,619 | 3.7% |
| Crinetics Pharmaceuticals Inc.(CRNX) | Common | 22663K107 | $22.5M | 480,588 | 3.6% |
| Olema Pharmaceuticals, Inc.(OLMA) | Common | 68062P106 | $22.1M | 1,953,690 | 3.6% |
| Madrigal Pharmaceuticals inc(MDGL) | Common | 558868105 | $16.4M | 61,399 | 2.6% |
| Natera Inc(NTRA) | Common | 632307104 | $15.8M | 172,413 | 2.5% |
| Werewolf Therapeutics, Inc.(HOWL) | Common | 95075A107 | $15.5M | 2,388,011 | 2.5% |
| Moonlake Immunotherapeutics(MLTX) | Class A Ord | 61559X104 | $14.9M | 296,050 | 2.4% |
| Avadel Pharmaceuticals PLC | Sponsored ADR | 05337M104 | $14.7M | 871,149 | 2.4% |
| Insmed Incorporated(INSM) | Common | 457669307 | $14.4M | 530,794 | 2.3% |
| ALX Oncology Holdings Inc.(ALXO) | Common | 00166B105 | $14.1M | 1,268,471 | 2.3% |
| Viking Therapeutics Inc(VKTX) | Common | 92686J106 | $12.3M | 150,000 | 2.0% |
| Intellia Therapeutics, Inc.(NTLA) | Common | 45826J105 | $11.9M | 432,598 | 1.9% |
| Regenxbio Inc.(RGNX) | Common | 75901B107 | $11.6M | 549,078 | 1.9% |
| Ultragenyx Pharmaceutical Inc(RARE) | Common | 90400D108 | $11.5M | 245,590 | 1.8% |
| Morphic Holding Inc | Common | 61775R105 | $11.5M | 325,333 | 1.8% |
| 89Bio Inc(ETNBGBP) | Common | 282559103 | $11.3M | 967,742 | 1.8% |
| Viridian Therapeutics Inc(VRDN) | Common | 92790C104 | $10.8M | 614,010 | 1.7% |
| Fulcrum Therapeutics Inc(FULC) | Common | 359616109 | $10.7M | 1,137,108 | 1.7% |
| Xeris Biopharma Holdings Inc(XERS) | Common | 98422E103 | $9.2M | 4,166,496 | 1.5% |
| Axsome Therapeutics, Inc.(AXSM) | Common | 05464T104 | $9.1M | 114,127 | 1.5% |
| Kalvista Pharmaceuticals Inc(KALV) | Common | 483497103 | $9.0M | 760,722 | 1.5% |
| Revolution Medicines, Inc.(RVMD) | Common | 76155X100 | $8.8M | 273,217 | 1.4% |
| Verve Therapeutics, Inc | Common | 92539P101 | $8.5M | 638,163 | 1.4% |
| Amicus Therapeutics Inc.(FOLD) | Common | 03152W109 | $8.5M | 718,970 | 1.4% |
| Akero Therapeutics Inc(AKRO) | Common | 00973Y108 | $8.4M | 332,924 | 1.4% |
| Adaptimmune Therapeutics plc(ADAPY) | Sponsored ADR | 00653A107 | $8.1M | 5,095,912 | 1.3% |
| Edgewise Therapeutics Inc(EWTX) | Common | 28036F105 | $8.0M | 441,259 | 1.3% |
| Repare Therapeutics, Inc.(RPTX) | Common | 760273102 | $7.7M | 1,639,849 | 1.2% |
| Relay Therapeutics Inc.(RLAY) | Common | 75943R102 | $6.9M | 832,017 | 1.1% |
| Disc Medicine Inc(IRON) | Common | 254604101 | $6.9M | 110,779 | 1.1% |
| Trevi Therapeutics Inc(TRVI) | Common | 89532M101 | $4.6M | 1,340,960 | 0.7% |
| Immatics NV | Common | N44445909 | $4.2M | 395,237 | 0.7% |
| Compass Therapeutics, Inc.(CMPX) | Common | 20454B104 | $3.9M | 1,971,402 | 0.6% |